MetLife Investment Management
TSHA icon

MetLife Investment Management’s Taysha Gene Therapies TSHA Stock Holding History

MetLife Investment Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$959K Buy
140,846
+20,730
+17% +$123K ﹤0.01% 1550
2026
Q1 		$537K Buy
120,116
+6,850
+6% +$31.9K ﹤0.01% 1727
2025
Q4 		$623K Sell
113,266
-13,778
-11% -$66.9K ﹤0.01% 1685
2025
Q3 		$415K Buy
127,044
+18,966
+18% +$53.7K ﹤0.01% 1893
2025
Q2 		$250K Buy
108,078
+367
+0.3% +$797 ﹤0.01% 2070
2025
Q1 		$150K Buy
107,711
+44,721
+71% +$74.8K ﹤0.01% 2344
2024
Q4 		$109K Sell
62,990
-13,047
-17% -$27.1K ﹤0.01% 2580
2024
Q3 		$153K Buy
76,037
+34,243
+82% +$75.1K ﹤0.01% 2428
2024
Q2 		$93.6K Buy
+41,794
New +$122K ﹤0.01% 2638
2022
Q1 		– Sell
-9,509
Closed -$111K – 2774
2021
Q4 		$111K Hold
9,509
– – ﹤0.01% 2374
2021
Q3 		$177K Hold
9,509
– – ﹤0.01% 2171
2021
Q2 		$202K Buy
+9,509
New +$219K ﹤0.01% 2170

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MetLife Investment Management's TSHA Position: Q2 2026 in Review

MetLife Investment Management increased its Taysha Gene Therapies (TSHA) stake by 17% in Q2 2026, buying an estimated $123K and bringing the position to 140,846 shares worth $959K. The position accounts for ﹤0.01% of the portfolio, ranked #1550.

MetLife Investment Management first reported a position in TSHA in Q2 2021 and has held it in 12 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • MetLife Investment Management held 140,846 shares of Taysha Gene Therapies worth $959K as of Q2 2026.
  • MetLife Investment Management bought 20,730 Taysha Gene Therapies shares in Q2 2026, an estimated $123K.
  • Taysha Gene Therapies made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1550 holding.
  • MetLife Investment Management first reported a position in Taysha Gene Therapies in Q2 2021 and has held it in 12 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.